Sun Pharmaceuticals has received an approval from the Subject Expert Committee (SEC) functional under CDSCO Central Drugs Standard Control Organization, to manufacture Dextromethorphan Hydrobromide 30mg and Chlorpheniramine maleate IP 4mg sustained-release Oral suspension.
Although the approval came with the condition that the firm should conduct a Phase-IV clinical trial and, accordingly, the Phase-IV protocol should be submitted within 03 months from the date of approval.
The committee reviewed the proposal and noted that the FDC of Dextromethorphan Hydrobromide 10mg + Chlorphenaramine maleate 2mg per 5ml is already approved by DCGI.
Dextromethophan, an antitussive agent, is primarily used as a cough suppressant to relieve cough caused by mild throat and bronchial inflammation (such as that which often occurs with the flu and common cold), as well as cough caused by inhaled particle irritants.
Chlorpheniramine is an antihistamine used to control allergies, high fever, and the common cold.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…